Inclusion Criteria:

- Patients with advanced solid tumors with previous treatment or beyond standard
therapy of significant clinical benefit

- Therapy with no more than 3 prior chemotherapy regimens

- Radiotherapy to less than 25% of bone marrow volume (no pelvic radiation)

- Adequate organ function

- Recovery from the effects of prior chemotherapy and radiation therapy, with at least
a 4 week interval. All prior toxicities should have resolved to baseline prior to
entry into the study.

- Good performance status

- Anticipate life expectancy of at least 6 months

- Not pregnant or lactating.

- Sexually active men and women of childbearing age must use adequate contraception.

- Be able to give signed, written informed consent.

- No gastrointestinal condition that could affect the absorption of the drug

- No active infection requiring systemic medical therapy one week prior to chemotherapy